Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study (GPAC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00346398|
Recruitment Status : Completed
First Posted : June 29, 2006
Results First Posted : December 16, 2013
Last Update Posted : May 1, 2017
|Condition or disease||Intervention/treatment||Phase|
|Asthma Allergic Sensitization||Biological: Oral mucosal immunoprophylaxis (OMIP) Biological: Placebo||Phase 2|
Researchers suspect that allergies to common inhaled allergens (such as house dust mite, cat dander, and grass pollens) are a major cause of childhood asthma. Recent evidence suggests that if allergies to inhaled allergens are prevented, this can cause changes in the immune system that may inhibit the development of asthma. Although strategies to prevent allergies generally focus on avoiding the allergen, complete avoidance of the common allergens linked to asthma would require extreme measures and is impractical.
Oral mucosal immunoprophylaxis (OMIP) therapy is an allergy treatment that can induce long-lasting immune tolerance in people already suffering from allergies. By exposing the patient to small, repeated, but increasing doses of the problem allergen over a long period of time, the patient's immune system is eventually desensitized to that particular allergen. OMIP therapy has been shown to be safe in children as young as 2 years old. This study will evaluate if OMIP therapy against common inhaled allergens is safe and effective in preventing the development of asthma in children at high risk for developing the disease. Children enrolled in this study have been diagnosed with eczema or food allergies and have a family history of eczema, allergic rhinitis, or asthma.
There are two groups in this study. The experimental arm participants will receive OMIP therapy (a mixture of house dust mite, cat, and timothy grass allergens) as daily oral drops under the tongue for 1 year; Placebo arm participants will receive an allergen free placebo solution. Participants will be followed for an additional 3 years to see whether they develop allergies or asthma and to determine how OMIP affects their immune system's response to allergens. There will be 5 study visits in the first year and 6 visits over the next 3 years. At all visits, participants will be assessed for allergy/asthma symptoms, will be asked to complete questionnaires, and may be asked to provide blood or saliva samples.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||51 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease (ITN025AD)|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||July 2011|
|Actual Study Completion Date :||July 2011|
Experimental: Oral mucosal immunoprophylaxis (OMIP)
Participants are administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months.
Biological: Oral mucosal immunoprophylaxis (OMIP)
OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
Other Name: Allergen immunotherapy
Placebo Comparator: Placebo
Participants are administered, via the same route as the experimental group, an oral placebo solution daily for 12 months.
The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
- Number of Participants With Allergic Sensitization at Month 36 Status Post Treatment Completion [ Time Frame: Three years (36 months) after Treatment Completion ]
Allergic sensitization is defined as a positive serum allergen specific Immunoglobulin E (IgE) CAP test or a positive allergy skin prick test. Not experiencing allergic sensitization is the better outcome for this measure.
- A positive serum allergen specific IgE CAP (ImmunoCAP) test result is defined by a result >= 0.35 kU/L. Higher scores indicate greater allergic sensitization.
- A positive skin prick test is defined as a wheal diameter that is 3 mm larger than that produced by a negative control. Higher wheal sizes indicate greater allergic reaction or sensitization.
- Number of Participants With Current Asthma at Month 36 Status Post Treatment Completion [ Time Frame: Three years (36 months) after Treatment Completion ]Participants who currently have asthma three years after end of treatment. Asthma is defined as three distinct episodes of wheeze after the first year of life, each of which lasts 3 or more consecutive days and occurs in a clinical setting where asthma is likely and other likely conditions have been excluded. Episodes must be separated by at least 7 days without wheeze. Current asthma is defined as a diagnosis of asthma and at least one episode of wheeze lasting 3 or more consecutive days in the past 12 months.
- Time to First Onset of Asthma [ Time Frame: From Treatment Initiation to Month 36 Status Post Treatment Completion ]Time to first onset of asthma is the time from the day a participant is randomized and initiates study treatment to the diagnosis of the first of three episodes of asthma. Asthma is defined as three distinct episodes of wheeze after the first year of life, each of which lasts 3 or more consecutive days and occurs in a clinical setting where asthma is likely and other likely conditions have been excluded. Episodes must be separated by at least 7 days without wheeze.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00346398
|United States, New York|
|Mount Sinai School of Medicine|
|New York, New York, United States, 10029|
|Royal Children's Hospital|
|Melbourne, Victoria, Australia, 3052|
|Australia, Western Australia|
|Telethon Institute for Child Health Research|
|Perth, Western Australia, Australia, 6008|
|Principal Investigator:||Patrick Holt, MD||Telethon Institute for Child Health Research|
|Study Chair:||Peter Sly, MD||Telethon Institute for Child Health Research|